비경구약 시장 보고서 : 동향, 예측, 경쟁 분석(-2031년)

The future of the global parenteral drug market looks promising with opportunities in the hospital and medical center markets. The global parenteral drug market is expected to grow with a CAGR of 4.1% from 2025 to 2031. The major drivers for this market are the increasing demand for biologic therapies, the rising prevalence of chronic diseases, and the growing adoption of injectable drugs.

• Lucintel forecasts that, within the type category, LVP drug is expected to witness higher growth over the forecast period.
• Within the application category, medical center is expected to witness higher growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Parenteral Drug Market

The parenteral drug market is undergoing significant transformation, driven by scientific breakthroughs, evolving patient needs, and advancements in drug delivery technologies. These emerging trends are shaping the future of pharmaceutical manufacturing and patient care.

• Rise of Biologics and Biosimilars: The increasing development and approval of biologic drugs, including monoclonal antibodies, gene therapies, and cell therapies, are a major trend. As these large-molecule drugs often require parenteral administration, their growth directly fuels the demand for injectable formulations and advanced delivery systems.
• Patient-Centric Delivery Devices: There's a strong trend towards developing user-friendly parenteral drug delivery devices for self-administration at home. Innovations like prefilled syringes, auto-injectors, and wearable injectors are improving patient adherence, convenience, and reducing the burden on healthcare facilities, especially for chronic conditions.
• Long-Acting Injectables: The market is seeing a growing emphasis on long-acting injectable formulations that reduce dosing frequency and improve patient compliance. LAIs are particularly beneficial for managing chronic diseases like schizophrenia, diabetes, and HIV, offering sustained drug release and enhancing therapeutic outcomes.
• Sterile Manufacturing Advancements: With the increasing complexity of biologic drugs and the need for high-potency compounds, advancements in aseptic processing and sterile manufacturing technologies are critical. This includes the adoption of isolator technology, robotic fill-finish lines, and stringent quality control to ensure product safety and integrity.
• Personalized Medicine & Targeted Therapies: The shift towards personalized medicine, where treatments are tailored to individual patient profiles, often involves parenteral administration of highly specific drugs. This trend drives demand for small-batch manufacturing capabilities and specialized delivery systems for targeted therapies.

These trends are significantly reshaping the parenteral drug market by fostering the development of complex and high-value therapeutics, enhancing patient convenience through innovative delivery methods, improving treatment adherence, and driving advancements in sterile manufacturing processes.

Recent Developments in the Parenteral Drug Market

The parenteral drug market is experiencing robust growth and continuous innovation, driven by the increasing global burden of chronic diseases and advancements in pharmaceutical science. These developments are enhancing drug efficacy, patient convenience, and overall healthcare delivery.

• Increased Biologic Drug Development: A significant development is the surge in research, development, and approval of biologic drugs, including monoclonal antibodies and advanced therapies. These complex molecules primarily require parenteral administration, directly fueling demand for specialized injectable formulations and sophisticated delivery solutions.
• Patient Self-Administration Devices: There's a notable development in the proliferation of user-friendly parenteral devices designed for home use. Prefilled syringes, auto-injectors, and wearable injectors are becoming more common, empowering patients to self-administer medications conveniently, thereby improving treatment adherence and reducing healthcare costs.
• Advancements in Sterile Manufacturing: Recent developments highlight continuous improvements in sterile manufacturing capabilities, including the adoption of isolator technologies and robotic fill-finish lines. This ensures higher levels of sterility and quality for injectable drugs, crucial for sensitive biologics and high-potency compounds.
• Focus on Long-Acting Formulations: The development of long-acting injectable formulations is a key recent trend. These innovative formulations reduce the frequency of injections, offering improved patient compliance and sustained therapeutic effects for chronic disease management, impacting patient outcomes positively.
• Expansion of Contract Manufacturing Organizations: CMOs are significantly expanding their parenteral manufacturing capacities and expertise. This development allows pharmaceutical companies to outsource complex sterile fill-finish operations, accelerating drug development and commercialization, especially for small and mid-sized biotech firms.

These developments are profoundly impacting the parenteral drug market by expanding the range of treatable conditions, enhancing patient access and convenience, ensuring higher product quality, improving adherence to medication regimens, and streamlining the drug development and manufacturing processes.

Strategic Growth Opportunities in the Parenteral Drug Market

The parenteral drug market offers substantial strategic growth opportunities across various applications, driven by evolving medical needs, technological advancements, and a focus on patient convenience. Capitalizing on these opportunities is key for market players.

• Oncology and Autoimmune Diseases: The high prevalence of cancer and autoimmune disorders, coupled with the increasing development of targeted biologic therapies, presents significant growth. Parenteral administration is crucial for these high-potency drugs, making this a prime area for specialized injectable formulations and delivery devices.
• Chronic Disease Management: The rising global burden of chronic conditions like diabetes, cardiovascular diseases, and neurological disorders offers a major opportunity. Developing long-acting injectables and user-friendly self-administration devices for these conditions can improve patient adherence and quality of life, driving market expansion.
• Vaccines and Gene Therapies: The ongoing development of new vaccines and the emergence of gene therapies represent a high-growth segment. These often require precise parenteral delivery, creating opportunities for advanced prefilled syringes, multi-dose vials, and novel delivery platforms to ensure effective administration.
• Home Healthcare and Self-Administration: The shift towards home-based care for many conditions creates a strong opportunity for parenteral drugs designed for patient self-administration. Investing in ergonomic auto-injectors, wearable pumps, and supportive digital health solutions can capture this expanding market segment.
• Biosimilar Development and Manufacturing: As patents for various biologics expire, the biosimilar market is booming, often requiring parenteral administration. Focusing on efficient and cost-effective manufacturing of biosimilar injectables, including fill-finish services, presents a significant opportunity for both pharmaceutical companies and CMOs.

These strategic growth opportunities are significantly impacting the parenteral drug market by fostering innovation in high-demand therapeutic areas, enhancing patient accessibility and adherence through convenient delivery systems, and driving the development of cost-effective alternatives in critical drug categories.

Parenteral Drug Market Driver and Challenges

The parenteral drug market is influenced by a dynamic interplay of various technological, economic, and regulatory factors. These elements serve as both significant drivers propelling market expansion and crucial challenges that necessitate strategic responses from industry participants.

The factors responsible for driving the parenteral drug market include:

1. Increasing Chronic Disease Prevalence: The global rise in chronic diseases such as cancer, diabetes, and autoimmune disorders significantly drives the parenteral drug market. These conditions often require long-term treatment with high-potency drugs best delivered via injection, ensuring effective and reliable therapeutic outcomes.

2. Growth of Biologics and Biosimilars: The escalating development and market penetration of complex biologic drugs (e.g., monoclonal antibodies, cell and gene therapies) and their biosimilar counterparts is a major driver. Due to their molecular structure, these therapies almost exclusively require parenteral administration, fueling demand for injectables.

3. Technological Advancements in Delivery Systems: Innovations in parenteral drug delivery, including prefilled syringes, auto-injectors, and wearable injectors, enhance patient convenience, safety, and adherence. These advancements facilitate self-administration, reduce healthcare burden, and significantly expand the market.

4. Rising Geriatric Population: The global increase in the elderly population contributes to market growth, as older individuals are more susceptible to chronic diseases requiring parenteral treatments. Additionally, parenteral administration can be easier for patients with swallowing difficulties or impaired gastrointestinal absorption.

5. Increased Focus on Personalized Medicine: The shift towards personalized and targeted therapies often involves highly potent drugs delivered parenterally to specific sites or patient subsets. This trend drives demand for customized injectable formulations and precision delivery systems, enhancing treatment efficacy.

Challenges in the parenteral drug market are:

1. High Manufacturing Costs: The production of parenteral drugs demands stringent sterile environments, specialized equipment, and complex quality control processes. These requirements lead to significantly higher manufacturing costs compared to oral solid dosage forms, impacting profitability and product pricing.

2. Stringent Regulatory Requirements: Parenteral drugs are subject to very strict regulatory oversight due to their direct entry into the bloodstream, necessitating rigorous testing for sterility, pyrogens, and particulate matter. Navigating diverse and evolving global regulations poses a significant challenge for manufacturers, affecting approval timelines.

3. Risk of Needlestick Injuries and Patient Compliance: Despite advancements, the use of needles for parenteral administration carries risks like needlestick injuries and can cause fear or discomfort, potentially leading to poor patient compliance. This challenge necessitates continuous innovation in safer and more patient-friendly delivery devices.

These drivers and challenges on the parenteral drug market is one of sustained growth, fueled by medical necessity and technological innovation. However, addressing the inherent complexities of manufacturing, stringent regulatory demands, and patient-related challenges will be crucial for broader accessibility and continued market expansion.

List of Parenteral Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies parenteral drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the parenteral drug companies profiled in this report include-

• Ostuka Pharmaceutical
• Teva Pharmaceutical Industries
• Kelun Pharma
• Cook Pharmica
• Patheon
• BAG Healthcare
• Beximco Pharma
• Baxter Healthcare Corporation
• B. Braun
• Fresenius

Parenteral Drug Market by Segment

The study includes a forecast for the global parenteral drug market by type, application, and region.

Parenteral Drug Market by Type [Value from 2019 to 2031]:

• LVP Drug
• SVP Drug

Parenteral Drug Market by Application [Value from 2019 to 2031]:

• Hospital
• Medical Centers
• Others

Parenteral Drug Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Parenteral Drug Market

The parenteral drug market is experiencing dynamic growth, driven by the increasing prevalence of chronic diseases, advancements in biotechnology, and the rising demand for targeted therapies. This market, encompassing injectable drugs, plays a critical role in delivering high-potency and complex molecules, and is evolving rapidly with innovations in drug delivery systems and manufacturing processes globally.

• United States: The U.S. parenteral drug market is expanding significantly due to the increasing demand for biologics and targeted therapies, particularly for chronic diseases like cancer and diabetes. There's a notable shift towards home healthcare, driven by the development of patient-friendly self-administration devices like prefilled syringes and auto-injectors, enhancing patient convenience and reducing hospital visits.
• China: China parenteral drug market is witnessing robust growth, fueled by rising healthcare expenditure, a large aging population, and increasing prevalence of chronic diseases. Recent developments include significant investments in local manufacturing capabilities for injectable drugs, with a focus on improving new drug approval timelines and enhancing overall pharmaceutical presence.
• Germany: Germany pharmaceutical market, a key player in Europe, sees parenteral delivery rising steadily. Driven by strong biopharmaceutical investments, an aging population, and a focus on specialized therapies, there's increased capacity for complex biologics. Recent acquisitions and expansions in sterile manufacturing facilities further bolster its position in parenteral drug production.
• India: India parenteral drug market is experiencing growth driven by increased healthcare access, rising chronic disease burden, and a growing pharmaceutical manufacturing sector. Indian companies are actively launching new product lines and expanding manufacturing capabilities for injectable drugs, focusing on both domestic demand and export opportunities, indicating a dynamic market.
• Japan: Japan parenteral drug market is influenced by its aging population and a focus on innovative therapies, including gene therapies and antibody-drug conjugates, which often require parenteral administration. Recent regulatory reforms aim to streamline drug development and accelerate market access for novel medicines, indicating a push towards high-value injectable treatments.

Features of the Global Parenteral Drug Market

• Market Size Estimates: Parenteral drug market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Parenteral drug market size by type, application, and region in terms of value ($B).
• Regional Analysis: Parenteral drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different type, applications, and regions for the parenteral drug market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the parenteral drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the parenteral drug market by type (LVP drug and SVP drug), application (hospital, medical centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Parenteral Drug Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 LVP Drug: Trends and Forecast (2019-2031)
• 4.4 SVP Drug: Trends and Forecast (2019-2031)

5. Global Parenteral Drug Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Hospitals: Trends and Forecast (2019-2031)
• 5.4 Medical Centers: Trends and Forecast (2019-2031)
• 5.5 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Parenteral Drug Market by Region

7. North American Parenteral Drug Market

• 7.1 Overview
• 7.2 North American Parenteral Drug Market by Type
• 7.3 North American Parenteral Drug Market by Application
• 7.4 United States Parenteral Drug Market
• 7.5 Mexican Parenteral Drug Market
• 7.6 Canadian Parenteral Drug Market

8. European Parenteral Drug Market

• 8.1 Overview
• 8.2 European Parenteral Drug Market by Type
• 8.3 European Parenteral Drug Market by Application
• 8.4 German Parenteral Drug Market
• 8.5 French Parenteral Drug Market
• 8.6 Spanish Parenteral Drug Market
• 8.7 Italian Parenteral Drug Market
• 8.8 United Kingdom Parenteral Drug Market

9. APAC Parenteral Drug Market

• 9.1 Overview
• 9.2 APAC Parenteral Drug Market by Type
• 9.3 APAC Parenteral Drug Market by Application
• 9.4 Japanese Parenteral Drug Market
• 9.5 Indian Parenteral Drug Market
• 9.6 Chinese Parenteral Drug Market
• 9.7 South Korean Parenteral Drug Market
• 9.8 Indonesian Parenteral Drug Market

10. ROW Parenteral Drug Market

• 10.1 Overview
• 10.2 ROW Parenteral Drug Market by Type
• 10.3 ROW Parenteral Drug Market by Application
• 10.4 Middle Eastern Parenteral Drug Market
• 10.5 South American Parenteral Drug Market
• 10.6 African Parenteral Drug Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Parenteral Drug Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 Ostuka Pharmaceutical
  • Company Overview
  • Parenteral Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Teva Pharmaceutical Industries
  • Company Overview
  • Parenteral Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Kelun Pharma
  • Company Overview
  • Parenteral Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Cook Pharmica
  • Company Overview
  • Parenteral Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Patheon
  • Company Overview
  • Parenteral Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 BAG Healthcare
  • Company Overview
  • Parenteral Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Beximco Pharma
  • Company Overview
  • Parenteral Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 Baxter Healthcare Corporation
  • Company Overview
  • Parenteral Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 B. Braun
  • Company Overview
  • Parenteral Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 Fresenius
  • Company Overview
  • Parenteral Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us